NL300415I2 - - Google Patents

Download PDF

Info

Publication number
NL300415I2
NL300415I2 NL300415C NL300415C NL300415I2 NL 300415 I2 NL300415 I2 NL 300415I2 NL 300415 C NL300415 C NL 300415C NL 300415 C NL300415 C NL 300415C NL 300415 I2 NL300415 I2 NL 300415I2
Authority
NL
Netherlands
Application number
NL300415C
Other languages
Dutch (nl)
Other versions
NL300415I1 (nl
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9906437.0A external-priority patent/GB9906437D0/en
Priority claimed from GBGB9909077.1A external-priority patent/GB9909077D0/en
Priority claimed from GBGB9909466.6A external-priority patent/GB9909466D0/en
Priority claimed from GBGB9916677.9A external-priority patent/GB9916677D0/en
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of NL300415I1 publication Critical patent/NL300415I1/nl
Publication of NL300415I2 publication Critical patent/NL300415I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NL300415C 1999-03-19 2009-09-24 Vaccin tegen antigenen van bacteriƫn NL300415I1 (nl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9906437.0A GB9906437D0 (en) 1999-03-19 1999-03-19 Vaccine
GBGB9909077.1A GB9909077D0 (en) 1999-04-20 1999-04-20 Novel compositions
GBGB9909466.6A GB9909466D0 (en) 1999-04-23 1999-04-23 Vaccines
GBGB9916677.9A GB9916677D0 (en) 1999-07-15 1999-07-15 Vaccine
PCT/EP2000/002468 WO2000056360A2 (en) 1999-03-19 2000-03-17 Vaccine against antigens from bacteriae

Publications (2)

Publication Number Publication Date
NL300415I1 NL300415I1 (nl) 2009-12-01
NL300415I2 true NL300415I2 (instruction) 2016-12-13

Family

ID=27451884

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300415C NL300415I1 (nl) 1999-03-19 2009-09-24 Vaccin tegen antigenen van bacteriƫn

Country Status (32)

Country Link
US (8) US20030147922A1 (instruction)
EP (6) EP1162998B1 (instruction)
JP (4) JP2002540074A (instruction)
KR (3) KR100642044B1 (instruction)
CN (3) CN1191852C (instruction)
AR (3) AR022964A1 (instruction)
AT (3) ATE346608T1 (instruction)
AU (3) AU750913B2 (instruction)
BE (1) BE1025464I2 (instruction)
BR (4) BRPI0009163B8 (instruction)
CA (3) CA2365296A1 (instruction)
CY (3) CY1107561T1 (instruction)
CZ (3) CZ20013378A3 (instruction)
DE (4) DE60038166T2 (instruction)
DK (2) DK1162999T3 (instruction)
ES (3) ES2339737T3 (instruction)
FR (1) FR10C0008I2 (instruction)
HK (3) HK1043730A1 (instruction)
HU (4) HU228499B1 (instruction)
IL (5) IL145044A0 (instruction)
LU (1) LU91652I2 (instruction)
MX (1) MXPA01009452A (instruction)
MY (2) MY125202A (instruction)
NL (1) NL300415I1 (instruction)
NO (4) NO330736B1 (instruction)
NZ (3) NZ513840A (instruction)
PL (3) PL203917B1 (instruction)
PT (2) PT1162999E (instruction)
SI (2) SI1162999T1 (instruction)
TR (3) TR200102736T2 (instruction)
TW (3) TWI281403B (instruction)
WO (3) WO2000056358A2 (instruction)

Families Citing this family (288)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US7078042B2 (en) * 1995-09-15 2006-07-18 Uab Research Foundation Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
ES2283012T3 (es) 1996-01-04 2007-10-16 Novartis Vaccines And Diagnostics, Inc. Bacterioferritina de helicobacter pylori.
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US20010016200A1 (en) 1998-04-23 2001-08-23 Briles David E. Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
EP1077722B1 (en) 1998-05-22 2006-08-09 Ottawa Health Research Institute Methods and products for inducing mucosal immunity
US6797275B1 (en) * 1998-12-04 2004-09-28 The United States Of America As Represented By The Department Of Health And Human Services Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
BRPI0009163B8 (pt) 1999-03-19 2021-05-25 Glaxosmithkline Biologicals Sa composiĆ§Ć£o imunogĆŖnica e vacina que a compreende
GB9925559D0 (en) * 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
NZ540544A (en) 2000-10-27 2007-08-31 Inst Genomic Research Nucleic acids and proteins from streptococcus groups A & B
GB2370770B (en) * 2001-01-03 2005-06-01 Simon Connolly Uses of Streptococcus Vaccines
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
DK2332581T3 (en) 2001-01-23 2015-10-05 Sanofi Pasteur Inc Tri- or tetravalent meningococcal polysaccharide-crm197 conjugate vaccine
EP1361890B1 (en) 2001-02-23 2011-03-30 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0109297D0 (en) * 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
DE60228758D1 (de) 2001-12-12 2008-10-16 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia tracheomatis
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
US7501134B2 (en) 2002-02-20 2009-03-10 Novartis Vaccines And Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
DE60328481D1 (de) * 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthƤlt
RU2378008C2 (ru) * 2002-05-14 2010-01-10 ŠŠ¾Š²Š°Ń€Ń‚Šøс Š’эŠŗсŠøŠ½ŠµŃ Š­Š½Š“ Š”Š°Š¹ŃŠ³Š½Š¾ŃŃ‚ŠøŠŗс Š”.Š .Š›. ŠšŠ¾Š¼Š±ŠøŠ½ŠøрŠ¾Š²Š°Š½Š½Ń‹Šµ Š²Š°ŠŗцŠøŠ½Ń‹ ŠæрŠ¾Ń‚ŠøŠ² Š±Š°ŠŗтŠµŃ€ŠøŠ°Š»ŃŒŠ½Š¾Š³Š¾ Š¼ŠµŠ½ŠøŠ½Š³ŠøтŠ° Š“Š»Ń Š²Š²ŠµŠ“ŠµŠ½Šøя чŠµŃ€ŠµŠ· сŠ»ŠøŠ·Šøстую Š¾Š±Š¾Š»Š¾Ń‡Šŗу
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
ES2608048T3 (es) 2002-10-11 2017-04-05 Glaxosmithkline Biologicals Sa Vacunas polipeptĆ­dicas para protecciĆ³n amplia contra linajes meningocĆ³cicos hipervirulentos
US7485710B2 (en) * 2002-10-15 2009-02-03 Intercell Ag Nucleic acids coding for adhesion factor of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof
ES2645924T3 (es) 2002-11-01 2017-12-11 Glaxosmithkline Biologicals S.A. Procedimiento de secado
PL229487B1 (pl) 2002-11-12 2018-07-31 Brigham & Womens Hospital Inc Kompozycja zawierająca polimer Ī²-1,6-glukozaminy, kompozycja zawierająca przeciwciało, kompozycja farmaceutyczna, sposĆ³b wytwarzania wyodrębnionego polisacharydu, sposĆ³b identyfikacji obecności deacetylowanej poli-N-acetyloglukozaminy (dPNAG) i/ lub poli-N-acetyloglukozaminy (PNAG), wyodrębniony polisacharyd do zastosowania w leczeniu lub profilaktyce zakażenia, wyodrębniony polisacharyd do zastosowania do wytwarzania przeciwciał, w tym przeciwciał monoklonalnych, wyodrębniony polisacharyd do zastosowania w identyfikacji przeciwciała monoklonalnego
PT2279746E (pt) 2002-11-15 2013-12-09 Novartis Vaccines & Diagnostic ProteĆ­nas de superfĆ­cie de neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP1578954A4 (en) 2002-12-11 2010-08-11 Coley Pharm Group Inc 5'-CPG NUCLEIC ACIDS AND USE METHOD
AU2003299994A1 (en) 2002-12-27 2004-07-29 Chiron Corporation Immunogenic compositions containing phospholpid
FR2850106B1 (fr) 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
PT1587537E (pt) 2003-01-30 2012-05-30 Novartis Ag Vacinas injetĆ”veis contra mĆŗltiplos serogrupos meningocĆ³cicos
NZ561879A (en) 2003-03-07 2009-05-31 Wyeth Corp Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
BRPI0408094A (pt) * 2003-03-13 2006-02-14 Glaxosmithkline Biolog Sa processo para purificaĆ§Ć£o de uma citolisina bacteriana, citolisina bacteriana, conjugado de polissacarƬdeo capsular-pneumolisina bacteriano, composiĆ§Ć£o imunogĆŖnica, vacina, processo de produĆ§Ć£o da vacina, mĆ©todo de tratamento ou prevenĆ§Ć£o de infecĆ§Ć£o por streptococcus pneumoniae, e, uso da pneumolisina ou do conjugado de polissacarƬdeo-pneumolisina bacteriano
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgĆ”nicos para la inmunopotenciaciĆ³n
WO2005020964A1 (en) 2003-06-02 2005-03-10 Chiron Corporation Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
DE602004032481D1 (de) * 2003-10-02 2011-06-09 Novartis Vaccines & Diagnostic Kombinationsimpfstoffe gegen Meningitis
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
US9402915B2 (en) 2004-04-30 2016-08-02 Glaxosmithkline Biologicals Sa Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
US7444197B2 (en) * 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
CA2571421A1 (en) 2004-06-24 2006-01-05 Nicholas Valiante Compounds for immunopotentiation
JP2008508320A (ja) 2004-07-29 2008-03-21 ć‚«ć‚¤ćƒ­ćƒ³ ć‚³ćƒ¼ćƒćƒ¬ć‚¤ć‚·ćƒ§ćƒ³ ļ¼³ļ½”ļ½’ļ½…ļ½ļ½”ļ½ļ½ƒļ½ļ½ƒļ½ƒļ½•ļ½“ļ½ļ½‡ļ½ļ½Œļ½ļ½ƒļ½”ļ½‰ļ½ļ½…ć®ć‚ˆć†ćŖć‚°ćƒ©ćƒ é™½ę€§ē“°čŒć«åÆ¾ć™ć‚‹å…ē–«åŽŸę€§ēµ„ęˆē‰©
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
US9034345B2 (en) 2005-01-27 2015-05-19 Children's Hospital & Research Center Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
LT2351772T (lt) 2005-02-18 2016-10-10 Glaxosmithkline Biologicals Sa Baltymai ir nukleorūgŔtys iŔ su meningitu/sepsiu susijusių escherichia coli
JP2008530245A (ja) 2005-02-18 2008-08-07 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ćƒ“ć‚”ć‚Æć‚·ćƒ³ć‚ŗ ć‚¢ćƒ³ćƒ‰ ćƒ€ć‚¤ć‚¢ć‚°ćƒŽć‚¹ćƒ†ć‚£ć‚Æć‚¹ļ¼Œ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ å°æč·Æē—…åŽŸę€§čŒę Ŗē”±ę„ć®ęŠ—åŽŸ
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
CN113198013B (zh) * 2005-04-08 2024-02-20 ęƒ ę°ęœ‰é™č“£ä»»å…¬åø 多价č‚ŗē‚ŽēƒčŒå¤šē³–ļ¼č›‹ē™½č“Øē¼€åˆē‰©ē»„合ē‰©
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US8119146B2 (en) 2005-04-18 2012-02-21 Angelica Medina-Selby Expressing hepatitis B virus surface antigen for vaccine preparation
PL2283857T3 (pl) 2005-06-27 2020-02-28 Glaxosmithkline Biologicals Sa Kompozycja szczepionki zawierająca skoniugowane natywne polisacharydy otoczkowe N. meningitidis
RU2457858C2 (ru) 2005-09-01 2012-08-10 ŠŠ¾Š²Š°Ń€Ń‚Šøс Š’эŠŗсŠøŠ½ŠµŃ Š­Š½Š“ Š”Š°Š¹ŃŠ³Š½Š¾ŃŃ‚ŠøŠŗс Š“Š¼Š±Ń… Š£Š½Š“ ŠšŠ¾ ŠšŠ³ ŠœŠ½Š¾Š¶ŠµŃŃ‚Š²ŠµŠ½Š½Š°Ń Š²Š°ŠŗцŠøŠ½Š°Ń†Šøя, Š²ŠŗŠ»ŃŽŃ‡Š°ŃŽŃ‰Š°Ń Š¼ŠµŠ½ŠøŠ½Š³Š¾ŠŗŠ¾ŠŗŠŗŠø сŠµŃ€Š¾Š³Ń€ŃƒŠæŠæы с
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
ES2514316T3 (es) 2005-11-22 2014-10-28 Novartis Vaccines And Diagnostics, Inc. PartĆ­culas similares a virus (VLPs) de Norovirus y Sapovirus
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa ꖰē©Žēµ„合ē‰©
HUE033081T2 (hu) * 2005-12-22 2017-11-28 Glaxosmithkline Biologicals Sa Streptococcus pneumoniae vakcina
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
SG175492A1 (en) * 2006-01-17 2011-11-28 Arne Forsgren A novel surface exposed haemophilus influenzae protein (protein e; pe)
CN101024079B (zh) * 2006-02-17 2012-02-01 ē¦å·žę˜Œę™–ē”Ÿē‰©å·„ēØ‹ęœ‰é™å…¬åø č‚ŗē‚Žé“¾ēƒčŒå¤šē³–-å¤–č†œč›‹ē™½ē»“合ē–«č‹—åŠåˆ¶å¤‡ę–¹ę³•
KR101411425B1 (ko) * 2006-03-17 2014-06-24 ė” ź±°ė²„ėؼķŠø ģ˜¤ėøŒ ė” ģœ ė‚˜ģ“ķ‹°ė“œ ģŠ¤ķ…Œģ“ģø  ģ˜¤ėøŒ ģ•„ė©”ė¦¬ģ¹“ ģ—ģ¦ˆ ė ˆķ”„ė¦¬ģ  ķ‹°ė“œ ė°”ģ“ ė” ģ„øķ¬ėŸ¬ķ…Œė¦¬ ģ˜¤ėøŒ ė” ė””ķŒŒķŠøėؼķŠø ģ˜¤ėøŒ ķ—¬ģŠ¤ ģ•¤ė“œ ķœ“ėؼ ģ„œė¹„ģ‹œģ¦ˆ ė³µķ•© ė‹¤ź°€ ė©“ģ—­ģ›ģ„± ģ½˜ģ„¬ź²Œģ“ķŠøģ˜ ģ œģ”° ė°©ė²•
CA2646993C (en) 2006-03-22 2016-01-26 Novartis Ag Regimens for immunisation with meningococcal conjugates
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
TWI494124B (zh) * 2006-03-30 2015-08-01 Glaxosmithkline Biolog Sa 免ē–«åŽŸēµ„合ē‰©
SG170090A1 (en) * 2006-03-30 2011-04-29 Glaxosmithkline Biolog Sa Immunogenic composition
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
US20110206692A1 (en) * 2006-06-09 2011-08-25 Novartis Ag Conformers of bacterial adhesins
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
JP2010500399A (ja) 2006-08-16 2010-01-07 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ å°æč·Æē—…åŽŸę€§å¤§č…ø菌ē”±ę„ć®å…ē–«åŽŸ
CN101522906B (zh) * 2006-10-10 2012-05-30 ęƒ ę°å…¬åø č‚ŗē‚Žé“¾ēƒčŒ3型多ē³–ēš„ēŗÆ化
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
SI2167121T1 (sl) * 2007-06-26 2015-12-31 Glaxosmithkline Biologicals S.A. Cepivo, ki obsega kapsularne polisaharidne konjugate Streptococcusa pneumoniae
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
ES2561483T3 (es) 2007-09-12 2016-02-26 Glaxosmithkline Biologicals Sa AntĆ­genos mutantes de GAS57 y anticuerpos de GAS57
BRPI0818545A2 (pt) 2007-10-19 2017-07-04 Novartis Ag formulaƧƵes de vacinais meningocĆ³cicas
JP2011503104A (ja) 2007-11-09 2011-01-27 ć‚«ćƒŖćƒ•ć‚©ćƒ«ćƒ‹ć‚¢ ć‚¤ćƒ³ć‚¹ćƒ†ć‚£ćƒ†ćƒ„ćƒ¼ćƒˆ ć‚Ŗ惖 惆ć‚Æ惎惭ć‚øćƒ¼ 免ē–«čŖæēƀ化合ē‰©ćŖć‚‰ć³ć«é–¢é€£ēµ„ęˆē‰©ćŠć‚ˆć³ę–¹ę³•
ES2664753T3 (es) 2007-12-07 2018-04-23 Glaxosmithkline Biologicals Sa Composiciones de inducciĆ³n de respuestas inmunes
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
JP5656642B2 (ja) 2007-12-21 2015-01-21 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ ć‚¹ćƒˆćƒ¬ćƒ—ćƒˆćƒŖć‚·ćƒ³ļ½ć®å¤‰ē•°ä½“å½¢ę…‹
EP2252326A4 (en) * 2008-02-01 2012-08-29 Newcastle Innovation Ltd VACCINE COMPOSITIONS
EP3263591B1 (en) 2008-02-21 2019-03-27 GlaxoSmithKline Biologicals S.A. Meningococcal fhbp polypeptides
AU2009223613B2 (en) 2008-03-10 2014-09-25 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
MX2011000823A (es) 2008-07-21 2011-04-11 Brigham & Womens Hospital Metodos y composiciones que se relacionan con oligosacaridos sinteticos de beta-1,6 glucosamina.
CN102264444B (zh) 2008-10-27 2015-08-05 čÆŗåŽč‚”ä»½ęœ‰é™å…¬åø ēŗÆåŒ–ę–¹ę³•
EP2376108B1 (en) 2008-12-09 2017-02-22 Pfizer Vaccines LLC IgE CH3 PEPTIDE VACCINE
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
EP2367568A2 (en) 2008-12-17 2011-09-28 Novartis AG Meningococcal vaccines including hemoglobin receptor
CN105056229A (zh) 2009-01-05 2015-11-18 埃ēš®ę‰˜å‰å°¼č„æę–Æč‚”ä»½ęœ‰é™å…¬åø 佐剂ē»„合ē‰©åŠä½æē”Øę–¹ę³•
MX2011007456A (es) 2009-01-12 2011-08-03 Novartis Ag Antigenos del dominio de proteina de superficie de union a colageno tipo b (can_b) en vacunas contra bacteria gram positiva.
BRPI1009829A2 (pt) 2009-03-24 2016-11-16 Novartis Ag combinaƧƵes de proteĆ­na de ligaĆ§Ć£o de fator h meningocĆ³cico e conjugados de sacarĆ­deos pneumocĆ³cicos
HUE049695T2 (hu) 2009-03-24 2020-10-28 Glaxosmithkline Biologicals Sa AdjuvĆ”lĆ³ H meningococcus faktort kƶtƵ fehĆ©rje
CA2758490C (en) 2009-04-14 2023-05-02 Novartis Ag Compositions for immunising against staphylococcus aureus
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
CN107096020A (zh) 2009-06-22 2017-08-29 ęƒ ę°ęœ‰é™č“£ä»»å…¬åø é‡‘é»„č‰²č‘”č„ēƒčŒęŠ—原ēš„免ē–«åŽŸę€§ē»„合ē‰©
AR077190A1 (es) 2009-06-22 2011-08-10 Wyeth Llc Composiciones y metodos para preparar composiciones inmunogenicas conjugadas de polisacaridos capsulares de staphylococcus aureus de los serotipos 5 y 8
US8647621B2 (en) 2009-07-27 2014-02-11 Fina Biosolutions, Llc Method of producing protein-carbohydrate vaccines reduced in free carbohydrate
IN2012DN00446A (instruction) 2009-07-30 2015-05-15 Pfizer Vaccines Llc
EP2470204B1 (en) 2009-08-27 2015-12-16 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
RU2538162C2 (ru) 2009-09-03 2015-01-10 ŠŸŃ„Š°Š¹Š·ŠµŃ€ Š’эŠŗсŠøŠ½Ń Š­Š»Š­Š»Š”Šø Š’Š°ŠŗцŠøŠ½Š° ŠæрŠ¾Ń‚ŠøŠ² pcsk9
JP2013504556A (ja) 2009-09-10 2013-02-07 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ 갗道ē–¾ę‚£ć«åÆ¾ć™ć‚‹ēµ„ćæåˆć‚ć›ćƒÆć‚Æćƒćƒ³
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
SG10201407096RA (en) 2009-10-30 2014-12-30 Novartis Ag Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
BR122022002136B1 (pt) 2009-12-17 2022-08-23 Fina Biosolutions, Llc Processo de conjugaĆ§Ć£o de carboidratos na preparaĆ§Ć£o de vacinas conjugadas e suas respectivas vacinas
CA2785585A1 (en) 2009-12-22 2011-06-30 Celldex Therapeutics, Inc. Vaccine compositions
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
CN105315351A (zh) 2010-03-30 2016-02-10 å„„å…‹å…°å„æē«„医院及ē ”ē©¶äø­åæƒ ę”¹ę€§ēš„h因子ē»“åˆč›‹ē™½ļ¼ˆfhbpļ¼‰åŠå…¶ä½æē”Øę–¹ę³•
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011127302A2 (en) 2010-04-07 2011-10-13 Yue Shen Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
CA2800174A1 (en) * 2010-05-20 2011-11-24 June L. Round Antigen specific tregs and related compositions, methods and systems
JP2013532008A (ja) 2010-05-28 2013-08-15 惆惈ćƒŖć‚¹ ć‚Ŗćƒ³ćƒ©ć‚¤ćƒ³ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ åÆ¾č©±å¼ćƒć‚¤ćƒ–ćƒŖćƒƒćƒ‰éžåŒęœŸć‚³ćƒ³ćƒ”ćƒ„ćƒ¼ć‚æćƒ»ć‚²ćƒ¼ćƒ ćƒ»ć‚¤ćƒ³ćƒ•ćƒ©ć‚¹ćƒˆćƒ©ć‚Æćƒćƒ£
CN107080838A (zh) * 2010-06-04 2017-08-22 ęƒ ę°ęœ‰é™č“£ä»»å…¬åø ē–«č‹—制剂
WO2011154863A1 (en) 2010-06-07 2011-12-15 Pfizer Inc. Her-2 peptides and vaccines
EP2575868A1 (en) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
CA2803239A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
EP2655389A2 (en) 2010-12-24 2013-10-30 Novartis AG Compounds
WO2012103421A1 (en) 2011-01-27 2012-08-02 Novartis Ag Adjuvant nanoemulsions with crystallisation inhibitors
AU2012222883A1 (en) 2011-03-02 2013-10-17 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
ES2785108T3 (es) 2011-03-24 2020-10-05 Glaxosmithkline Biologicals Sa Nanoemulsiones adyuvantes con fosfolĆ­pidos
EP2511295A1 (en) 2011-04-15 2012-10-17 Institut National De La Sante Et De La Recherche Medicale Compositions for preventing and/or treating an infection by an HIV-1 virus
EP2705853B1 (en) 2011-05-06 2018-07-18 Aparin, Petr Gennadievich Exopolysaccharide of shigella sonnei bacteria, method for producing same, vaccine and pharmaceutical composition containing same
AU2012272652B2 (en) 2011-06-24 2017-06-01 Epitogenesis Inc. Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
JP6088507B2 (ja) 2011-07-08 2017-03-01 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ ćƒćƒ­ć‚·ćƒ³ćƒ©ć‚¤ć‚²ćƒ¼ć‚·ćƒ§ćƒ³ć®ę–¹ę³•
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
WO2013038375A2 (en) 2011-09-14 2013-03-21 Novartis Ag Methods for making saccharide-protein glycoconjugates
WO2013043518A1 (en) 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
JP6170932B2 (ja) 2011-11-07 2017-07-26 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ ļ½“ļ½ļ½’ļ¼ļ¼ļ¼™ļ¼–ęŠ—åŽŸćŠć‚ˆć³ļ½“ļ½ļ½’ļ¼’ļ¼ļ¼’ļ¼‘ęŠ—åŽŸć‚’å«ć‚€ć‚­ćƒ£ćƒŖć‚¢åˆ†å­
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
KR20140101835A (ko) 2011-12-08 2014-08-20 ė…øķŒŒė„“ķ‹°ģŠ¤ ģ•„ź²Œ ķ“ė”œģŠ¤ķŠøė¦¬ė“ ė””ķ”¼ģ‹¤ė ˆ ķ†”ģ‹ -źø°ė°˜ ė°±ģ‹ 
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
BR112014016223A8 (pt) 2011-12-29 2017-07-04 Novartis Ag combinaƧƵes adjuvantes de proteĆ­nas de ligaĆ§Ć£o de fator h meningocĆ³cico
CA2865028A1 (en) 2012-02-24 2013-08-29 Novartis Ag Pilus proteins and compositions
US20150132339A1 (en) 2012-03-07 2015-05-14 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
JP2015509963A (ja) 2012-03-08 2015-04-02 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ ļ¼“ļ½Œļ½’ļ¼”ć‚¢ć‚“ćƒ‹ć‚¹ćƒˆć‚’å«ć‚€ę··åˆćƒÆć‚Æćƒćƒ³
SA115360586B1 (ar) 2012-03-09 2017-04-12 ŁŲ§ŁŠŲ²Ų± Ų§Ł†Łƒ ŲŖŲ±ŁƒŁŠŲØŲ§ŲŖ Ł„Ų¹Ł„Ų§Ų¬ Ų§Ł„Ų§Ł„ŲŖŁ‡Ų§ŲØ Ų§Ł„Ų³Ų­Ų§Ų¦ŁŠ Ų§Ł„ŲØŁƒŲŖŁŠŲ±ŁŠ ŁˆŲ·Ų±Ł‚ Ł„ŲŖŲ­Ų¶ŁŠŲ±Ł‡Ų§
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
CN108671228A (zh) 2012-04-26 2018-10-19 čÆŗåŽč‚”ä»½ęœ‰é™å…¬åø ęŠ—åŽŸå’ŒęŠ—åŽŸē»„合
MX376235B (es) 2012-05-04 2025-03-07 Pfizer AntĆ­genos asociados a prĆ³stata y regĆ­menes de inmunoterapia basados en vacuna.
WO2013174832A1 (en) 2012-05-22 2013-11-28 Novartis Ag Meningococcus serogroup x conjugate
KR102057217B1 (ko) * 2012-06-20 2020-01-22 ģ—ģŠ¤ģ¼€ģ“ė°”ģ“ģ˜¤ģ‚¬ģ“ģ–øģŠ¤ ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
MX2015002717A (es) 2012-09-06 2015-05-15 Novartis Ag Vacunas combinadas con meningococo del serogrupo b y toxoides de difteria/tetanos/tosferina.
CN104717977A (zh) 2012-10-03 2015-06-17 čÆŗåŽč‚”ä»½ęœ‰é™å…¬åø 免ē–«åŽŸę€§ē»„合ē‰©
SG11201502599TA (en) 2012-10-12 2015-05-28 Glaxosmithkline Biolog Sa Non-cross-linked acellular pertussis antigens for use in combination vaccines
US20140193451A1 (en) * 2012-10-17 2014-07-10 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2014060383A1 (en) * 2012-10-17 2014-04-24 Glaxosmithkline Biologicals S.A. Immunogenic composition comprising 1 or more streptococcus pneumoniae capsular saccharide conjugates and a protein component comprising protein e and/or pila fromhaemophilus influenzae.
KR20140075201A (ko) * 2012-12-11 2014-06-19 ģ—ģŠ¤ģ¼€ģ“ģ¼€ėÆøģ¹¼ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
KR20140075196A (ko) 2012-12-11 2014-06-19 ģ—ģŠ¤ģ¼€ģ“ģ¼€ėÆøģ¹¼ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
TR201807340T4 (tr) 2013-02-01 2018-06-21 Glaxosmithkline Biologicals Sa Ƈan benzeri reseptƶr agonistleri iƧeren immĆ¼nolojik kompozisyonların intradermal yoldan verilmesi.
EP2994161B1 (en) 2013-05-10 2020-10-28 California Institute of Technology Probiotic prevention and treatment of colon cancer
CN105263517B (zh) 2013-05-15 2021-03-26 é˜æ尔ä¼Æč¾¾å¤§å­¦č‘£äŗ‹ä¼š E1e2hcvē–«č‹—及ä½æē”Øę–¹ę³•
CN103386126B (zh) * 2013-06-25 2015-06-17 北äŗ¬ē§‘å…“ē”Ÿē‰©åˆ¶å“ęœ‰é™å…¬åø äø€ē§å«č‚ é“ē—…ęÆ’ęŠ—åŽŸēš„多价免ē–«åŽŸę€§ē»„合ē‰©
MX380129B (es) 2013-09-08 2025-03-11 Pfizer Composiciones de neisseria meningitidis y sus metodos
WO2015095868A1 (en) * 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
CN105934251A (zh) 2014-01-21 2016-09-07 č¾‰ē‘žå¤§čÆ厂 č‚ŗē‚Žé“¾ēƒčŒčšč†œå¤šē³–及其ē¼€åˆē‰©
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
RU2771293C2 (ru) 2014-01-21 2022-04-29 ŠŸŃ„Š°Š¹Š·ŠµŃ€ Š˜Š½Šŗ. Š˜Š¼Š¼ŃƒŠ½Š¾Š³ŠµŠ½Š½Ń‹Šµ ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøцŠøŠø, сŠ¾Š“ŠµŃ€Š¶Š°Ń‰ŠøŠµ ŠŗŠ¾Š½ŃŠŃŽŠ³ŠøрŠ¾Š²Š°Š½Š½Ń‹Šµ ŠŗŠ°ŠæсуŠ»ŃŒŠ½Ń‹Šµ сŠ°Ń…Š°Ń€ŠøŠ“Š½Ń‹Šµ Š°Š½Ń‚ŠøŠ³ŠµŠ½Ń‹, Šø Šøх ŠæрŠøŠ¼ŠµŠ½ŠµŠ½ŠøŠµ
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
SI3110442T1 (sl) 2014-02-28 2021-01-29 Glaxosmithkline Biologicals S.A. Modificirani meningokokni fHbp polipeptidi
EP2921856B1 (en) * 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
CN104829711B (zh) * 2014-04-08 2018-04-03 北äŗ¬å¤©ęˆę–°č„‰ē”Ÿē‰©ęŠ€ęœÆęœ‰é™å…¬åø 脑膜ē‚ŽēƒčŒčšč†œå¤šē³–å•å…‹éš†ęŠ—ä½“åŠå…¶åŗ”ē”Ø
CA3212723A1 (en) 2014-07-23 2016-01-28 Peter T. Beernink Factor h binding protein variants and methods of use thereof
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3034516A1 (en) 2014-12-19 2016-06-22 Novartis AG Purification of streptococcal capsular polysaccharide
MX395525B (es) 2015-01-15 2025-03-25 Pfizer Composiciones inmunogenicas para usar en vacunas neumococicas.
CN104548090B (zh) * 2015-01-27 2016-11-30 äø­å›½ē§‘学院čæ‡ēØ‹å·„ē؋ē ”ē©¶ę‰€ äø€ē§Ī²-葔聚ē³–äæ®é„°ēš„č„‘č†œē‚Žå¤šē³–ē»“合ē–«č‹—åŠå…¶åˆ¶å¤‡ę–¹ę³•
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016201342A1 (en) 2015-06-10 2016-12-15 California Institute Of Technology Sepsis treatment and related compositions methods and systems
EP3109255A1 (en) 2015-06-26 2016-12-28 Institut National De La Recherche Agronomique Immunogenic composition
EP3319988A1 (en) 2015-07-07 2018-05-16 Affiris AG Vaccines for the treatment and prevention of ige mediated diseases
PE20240927A1 (es) 2015-07-21 2024-04-30 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos
CN107921113A (zh) 2015-08-25 2018-04-17 å·“ęƔ唔Ā·é˜æę ¼ę‹‰ę²ƒå°” 免ē–«č°ƒčŠ‚ē»„合ē‰©åŠå…¶ä½æē”Øę–¹ę³•
AU2016336150B2 (en) 2015-10-08 2023-08-10 The Governors Of The University Of Alberta Hepatitis C virus E1/E2 heterodimers and methods of producing same
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
US10786561B2 (en) 2015-11-20 2020-09-29 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
KR20180088458A (ko) 2015-12-04 2018-08-03 ė‹¤ė‚˜-ķŒŒė²„ ģŗ”ģ„œ ģøģŠ¤ķ‹°ķŠœķŠø ģøķ¬. ģ•”ģ˜ ģ¹˜ė£Œė„¼ ģœ„ķ•œ mica/b ģ•ŒķŒŒ 3 ė„ė©”ģøģ˜ ė°±ģ‹ ģ ‘ģ¢…
WO2017117539A1 (en) 2015-12-30 2017-07-06 Northwestern University Cell-free glycoprotein synthesis (cfgps) in prokaryotic cell lysates enriched with components for glycosylation
PL3405212T3 (pl) 2016-01-19 2020-11-16 Pfizer Inc. Szczepionki przeciwnowotworowe
US11612664B2 (en) 2016-04-05 2023-03-28 Gsk Vaccines S.R.L. Immunogenic compositions
WO2017220753A1 (en) 2016-06-22 2017-12-28 MAX-PLANCK-Gesellschaft zur Fƶrderung der Wissenschaften e.V. Pneumococcal polysaccharide-protein conjugate composition
US10829795B2 (en) 2016-07-14 2020-11-10 Northwestern University Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates
PH12019500238B1 (en) 2016-08-05 2023-05-10 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
MY199856A (en) 2016-08-05 2023-11-25 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2017321039B2 (en) 2016-09-02 2021-03-18 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
CN110022893B (zh) 2016-10-07 2023-12-29 ꁩē‰¹ē½—姆公åø ē”ØäŗŽē™Œē—‡ē–—ę³•ēš„免ē–«åŽŸę€§åŒ–合ē‰©
CN110022894B (zh) 2016-10-07 2024-01-19 ꁩē‰¹ē½—姆公åø ē”ØäŗŽē™Œē—‡ē–—ę³•ēš„免ē–«åŽŸę€§åŒ–合ē‰©
BE1025162B9 (fr) 2016-12-06 2019-01-07 Glaxosmithkline Biologicals Sa Procede de purification pour les polysaccharides capsulaires
AU2018208844B2 (en) 2017-01-20 2021-02-25 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
EP3577130A2 (en) 2017-01-31 2019-12-11 Pfizer Inc Neisseria meningitidis compositions and methods thereof
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
WO2018169303A1 (ko) * 2017-03-15 2018-09-20 ģ£¼ģ‹ķšŒģ‚¬ ģ—˜ģ§€ķ™”ķ•™ ė‹¤ź°€ ķė “źµ¬ź·  ė°±ģ‹  ģ”°ģ„±ė¬¼
BR112019020209A2 (pt) 2017-03-31 2020-06-02 Glaxosmithkline Intellectual Property Development Limited ComposiĆ§Ć£o imunogĆŖnica, uso de uma composiĆ§Ć£o imunogĆŖnica, mĆ©todo de tratamento ou prevenĆ§Ć£o de uma recorrĆŖncia de uma exacerbaĆ§Ć£o aguda de doenƧa pulmonar obstrutiva crĆ“nica, e, terapia de combinaĆ§Ć£o.
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
JP7132954B2 (ja) 2017-06-10 2022-09-07 ć‚¤ćƒ³ćƒ™ćƒ³ćƒˆćƒ—ćƒ©ć‚¤ć‚ŗ ćƒŖ惟惆惃惉 ćƒ©ć‚¤ć‚¢ćƒ“ćƒŖćƒ†ć‚£ ć‚«ćƒ³ćƒ‘ćƒ‹ćƒ¼ ę”¹å–„ć•ć‚ŒćŸå…ē–«åŽŸę€§åŠć³ēµåˆę“»ę€§ć‚’ęä¾›ć™ć‚‹ļ¼’ä¾”又ćÆå¤šä¾”ć‚³ćƒ³ć‚øćƒ„ć‚²ćƒ¼ćƒˆå¤šē³–ć‚’å«ć‚€å¤šä¾”ć‚³ćƒ³ć‚øćƒ„ć‚²ćƒ¼ćƒˆćƒÆć‚Æćƒćƒ³
EP3641808A1 (en) 2017-08-14 2020-04-29 GlaxoSmithKline Biologicals S.A. Methods of boosting immune responses
WO2019070994A1 (en) 2017-10-04 2019-04-11 Liffey Biotech Limited SACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE
PE20201338A1 (es) 2017-12-06 2020-11-25 Merck Sharp & Dohme Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y metodos de uso de estos
SG11202006388SA (en) 2018-02-05 2020-07-29 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
BR112020014978A2 (pt) 2018-02-05 2020-12-22 Sanofi Pasteur, Inc. ComposiĆ§Ć£o de conjugado polissacarĆ­deo-proteĆ­na pneumocĆ³cico multivalente
WO2019173438A1 (en) 2018-03-06 2019-09-12 Stc. Unm Compositions and methods for reducing serum triglycerides
PL3773689T3 (pl) 2018-04-11 2023-03-13 Enterome S.A. Peptydy antygenowe do zapobiegania i leczenia raka
US20210106652A1 (en) 2018-04-11 2021-04-15 Enterome S.A. Immunogenic Compounds For Treatment Of Fibrosis, Autoimmune Diseases And Inflammation
CN111989114A (zh) 2018-04-18 2020-11-24 Skē”Ÿē‰©ē§‘å­¦ę Ŗ式会ē¤¾ č‚ŗē‚Žé“¾ēƒčŒēš„čšč†œå¤šē³–仄及其免ē–«åŽŸę€§ē¼€åˆē‰©
CN112673054A (zh) 2018-07-19 2021-04-16 č‘›å…°ē“ å²åƆäøå…‹čŽ±ę©ē”Ÿē‰©ęœ‰é™å…¬åø ē”ØäŗŽåˆ¶å¤‡å¹²ē‡„多ē³–ēš„ę–¹ę³•
CA3107077A1 (en) 2018-08-07 2020-02-13 Glaxosmithkline Biologicals Sa Processes and vaccines
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
EP3893926A1 (en) 2018-12-12 2021-10-20 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
US20220054632A1 (en) 2018-12-12 2022-02-24 Glaxosmithkline Biologicals Sa Modified carrier proteins for o-linked glycosylation
MX2021007496A (es) 2018-12-19 2021-08-05 Merck Sharp & Dohme Llc Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y sus metodos de uso.
KR20210116512A (ko) 2019-01-11 2021-09-27 ė…øģ“°ģ›ØģŠ¤ķ„“ģœ ė‹ˆė²„ģ‹œķ‹° ģ›ķ•µģƒė¬¼ ģ„øķ¬ ģš©ķ•“ė¬¼ģ—ģ„œģ˜ ģƒģ²“ģ ‘ķ•©ģ²“ ė°±ģ‹  ķ•©ģ„±
US12397014B2 (en) 2019-02-05 2025-08-26 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
US20220118072A1 (en) 2019-02-11 2022-04-21 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ ē“°čŒå¤šē³–锞悒ē²¾č£½ć™ć‚‹ćŸć‚ć®ę–¹ę³•
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP3956666A1 (en) 2019-04-18 2022-02-23 GlaxoSmithKline Biologicals S.A. Antigen binding proteins and assays
US20220211859A1 (en) 2019-05-10 2022-07-07 Glaxosmithkline Biologicals Sa Conjugate production
CA3148928A1 (en) 2019-08-05 2021-02-11 Glaxosmithkline Biologicals Sa Process for preparing a composition comprising a protein d polypeptide
AU2020325645A1 (en) 2019-08-05 2022-02-17 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP4045150A1 (en) 2019-10-16 2022-08-24 Enterome S.A. Immunogenic compounds for treatment of adrenal cancer
EP4051696A1 (en) 2019-11-01 2022-09-07 Pfizer Inc. Escherichia coli compositions and methods thereof
MX2022005704A (es) 2019-11-15 2022-06-08 Enterome S A Peptidos antigenicos para la prevencion y el tratamiento de malignidad de celulas b.
BR112022008761A2 (pt) 2019-11-22 2022-07-26 Glaxosmithkline Biologicals Sa Dosagem e administraĆ§Ć£o de uma vacina de glicoconjugado de sacarĆ­deo
US20220409539A1 (en) * 2019-12-30 2022-12-29 Fraunhofer Usa Inc. Particles for multi-dose delivery
WO2021165847A1 (en) 2020-02-21 2021-08-26 Pfizer Inc. Purification of saccharides
CN115605498A (zh) 2020-02-23 2023-01-13 č¾‰ē‘žå…¬åøļ¼ˆUsļ¼‰ å¤§č‚ ę†čŒē»„合ē‰©åŠå…¶ę–¹ę³•
CN111588847B (zh) * 2020-05-18 2023-05-26 å¹æ州äø­åŒ»čÆ大学(å¹æ州äø­åŒ»čÆē ”ē©¶é™¢) äø€ē§å«ęœ‰å•ē£·é…ø化ēš„č„‚č“ØaäøŽē³–ęŠ—åŽŸēš„ē¼€åˆē‰©åŠå…¶åˆ¶å¤‡ę–¹ę³•å’Œåŗ”ē”Ø
EP4165064A2 (en) 2020-06-12 2023-04-19 GlaxoSmithKline Biologicals S.A. Dock tag system
US12053515B2 (en) 2020-08-10 2024-08-06 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F
KR20230096033A (ko) 2020-10-27 2023-06-29 ķ™”ģ“ģž ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ģ—ģŠ¤ģ¼€ė¦¬ķ‚¤ģ•„ ģ½œė¼ģ“ ģ”°ģ„±ė¬¼ ė° ź·øģ˜ ė°©ė²•
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
US20240000912A1 (en) 2020-11-04 2024-01-04 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US20230405137A1 (en) 2020-11-10 2023-12-21 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
CA3211240A1 (en) 2021-02-19 2022-08-25 Sanofi Pasteur Inc. Meningococcal b recombinant vaccine
JP2024510717A (ja) 2021-02-22 2024-03-11 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  免ē–«åŽŸę€§ēµ„ęˆē‰©ć€ä½æē”ØåŠć³ę–¹ę³•
EP4070814A1 (en) 2021-04-07 2022-10-12 Lama France Sars-cov-2 polypeptides and uses thereof
US20220387576A1 (en) 2021-05-28 2022-12-08 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20230175284A (ko) 2021-05-28 2023-12-29 ķ™”ģ“ģž ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ģ ‘ķ•©ėœ ķ”¼ė§‰ ģ‚¬ģ¹“ė¼ģ“ė“œ ķ•­ģ›ģ„ ķ¬ķ•Øķ•˜ėŠ” ė©“ģ—­ģ›ģ„± ģ”°ģ„±ė¬¼ ė° ź·øģ˜ ģš©ė„
AU2022391752A1 (en) 2021-11-18 2024-06-13 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20250163484A1 (en) 2022-02-25 2025-05-22 Pfizer Inc. Methods for Incorporating Azido Groups in Bacterial Capsular Polysaccharides
US20250205324A1 (en) 2022-03-31 2025-06-26 Enterome S.A. Antigenic peptides for prevention and treatment of cancer
JP2025516536A (ja) 2022-05-11 2025-05-30 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ äæå­˜å‰¤ć‚’ē”Ø恄恟ćƒÆć‚Æćƒćƒ³č£½å‰¤ć‚’ä½œč£½ć™ć‚‹ćŸć‚ć®ćƒ—ćƒ­ć‚»ć‚¹
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
AU2023385908A1 (en) 2022-11-22 2025-05-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP4626405A1 (en) 2022-12-01 2025-10-08 Pfizer Inc. Pneumococcal conjugate vaccine formulations
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024214016A1 (en) 2023-04-14 2024-10-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025109417A1 (en) 2023-11-21 2025-05-30 Panacea Biotec Limited Immunogenic composition of haemophilus influenzae conjugated to protein d
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
CN120404993B (zh) * 2025-07-03 2025-10-03 ęˆéƒ½čæˆē§‘åŗ·ē”Ÿē‰©ē§‘ęŠ€ęœ‰é™å…¬åø äø€ē§ę£€ęµ‹ę ·ęœ¬äø­mplēš„ę–¹ę³•åŠå…¶ē›ø关åŗ”ē”Ø

Family Cites Families (58)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
BE889979A (fr) 1981-08-14 1982-02-15 Smith Kline Rit Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation
US5360897A (en) * 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4882317A (en) * 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
HUT58804A (en) 1988-12-16 1992-03-30 James Cleland Paton Process for producing pneumolysine mutants and pneumococcus vaccines
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
EP0671948B1 (en) 1992-06-25 1997-08-13 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
AU5128593A (en) * 1992-09-16 1994-04-12 University Of Tennessee Research Corporation, The Antigen of hybrid m protein and carrier for group a streptococcal vaccine
CZ289476B6 (cs) 1993-03-23 2002-01-16 Smithkline Beecham Biologicals (S.A.) OčkovacĆ­ pÅ™Ć­pravek a zpÅÆsob jeho vĆ½roby
EP1300156A3 (en) 1993-05-18 2003-05-07 The Ohio State University Research Foundation Otitis media vaccine
ATE254475T1 (de) 1993-09-22 2003-12-15 Jackson H M Found Military Med Verfahren zur aktivierung von lƶslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5681570A (en) * 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
NZ306316A (en) * 1995-04-17 2001-06-29 Smithkline Beecham Biolog S use of lipoprotein and a type 2T independent antigen to induce an immune response to the antigen
UA56132C2 (uk) * 1995-04-25 2003-05-15 Š”Š¼Ń–Ń‚ŠŗŠ»Š°Š¹Š½ Š‘ічŠµŠ¼ Š‘Š°Š¹Š¾Š»Š¾Š“Š¶Ń–ŠŗŠ°Š»Ń Š”.Š. ŠšŠ¾Š¼ŠæŠ¾Š·Šøція Š²Š°ŠŗцŠøŠ½Šø (Š²Š°Ń€Ń–Š°Š½Ń‚Šø), сŠæŠ¾ŃŃ–Š± стŠ°Š±Ń–Š»Ń–Š·Š°Ń†Ń–Ń— qs21 Š²Ń–Š“Š½Š¾ŃŠ½Š¾ Š³Ń–Š“рŠ¾Š»Ń–Š·Ńƒ (Š²Š°Ń€Ń–Š°Š½Ń‚Šø), сŠæŠ¾ŃŃ–Š± ŠæрŠøŠ³Š¾Ń‚ŃƒŠ²Š°Š½Š½Ń ŠŗŠ¾Š¼ŠæŠ¾Š·Šøції Š²Š°ŠŗцŠøŠ½Šø
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
BR9609399A (pt) 1995-06-07 2001-08-28 Biochem Vaccines Inc Elementos de proteƬnas de choque tĆ©rmico estreptocĆ³cicos da famƬlia hsp70
US5736533A (en) * 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
AU695720B2 (en) 1995-06-07 1998-08-20 Smithkline Beecham Biologicals (Sa) Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
SE9601158D0 (sv) 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
US6245335B1 (en) * 1996-05-01 2001-06-12 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
AU732520B2 (en) 1996-05-01 2001-04-26 Rockefeller University, The Choline binding proteins for anti-pneumococcal vaccines
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
JPH102001A (ja) * 1996-06-15 1998-01-06 Okajima Kogyo Kk ć‚°ćƒ¬ćƒ¼ćƒćƒ³ć‚°
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
FR2763244B1 (fr) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
JP2001502925A (ja) 1997-06-03 2001-03-06 ć‚³ćƒŽćƒ¼ćƒˆ ćƒ©ćƒœćƒ©ćƒˆćƒŖćƒ¼ć‚ŗ ćƒŖ惟惆惃惉 ćƒ¢ćƒ©ć‚Æć‚»ćƒ©ć®ćƒ©ć‚Æ惈惕悧ćƒŖćƒ³å—å®¹ä½“éŗ伝子
WO1999003884A2 (en) 1997-07-21 1999-01-28 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
US6224880B1 (en) * 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
US20050031638A1 (en) * 1997-12-24 2005-02-10 Smithkline Beecham Biologicals S.A. Vaccine
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
US6709658B1 (en) * 1998-02-12 2004-03-23 Wyeth Holdings Corporation Pneumococcal vaccines formulated with interleukin-12
CN1200731C (zh) 1998-04-07 2005-05-11 免ē–«åŒ»ē–—å…¬åø ē”Ø作ē–«č‹—ēš„č‚ŗē‚ŽēƒčŒčƒ†ē¢±ē»“åˆč›‹ē™½č”ē”Ÿē‰©
GB9812613D0 (en) 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
CA2340692A1 (en) 1998-08-19 2000-03-02 North American Vaccine, Inc. Immunogenic .beta.-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide
EP1140157B1 (en) * 1998-12-21 2009-02-18 MedImmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
BRPI0009163B8 (pt) * 1999-03-19 2021-05-25 Glaxosmithkline Biologicals Sa composiĆ§Ć£o imunogĆŖnica e vacina que a compreende
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
CN201252175Y (zh) * 2008-08-04 2009-06-03 åƌ士åŗ·(ę˜†å±±)ē”µč„‘ęŽ„ę’ä»¶ęœ‰é™å…¬åø ēŗæē¼†čæžęŽ„å™Øē»„件

Also Published As

Publication number Publication date
US20110217329A1 (en) 2011-09-08
EP1163000B1 (en) 2008-02-27
KR20020000785A (ko) 2002-01-05
CA2366152A1 (en) 2000-09-28
CN100339130C (zh) 2007-09-26
CA2366314C (en) 2012-01-10
AR022963A1 (es) 2002-09-04
US9168313B2 (en) 2015-10-27
KR20020001785A (ko) 2002-01-09
EP1162998B1 (en) 2010-03-03
ATE459373T1 (de) 2010-03-15
PL355264A1 (en) 2004-04-05
DE60038166T2 (de) 2009-03-12
ES2300255T3 (es) 2008-06-16
NO20014325D0 (no) 2001-09-05
DE122009000054I1 (de) 2009-12-31
DE60038166D1 (de) 2008-04-10
AU3430700A (en) 2000-10-09
AU3291900A (en) 2000-10-09
HUP0200367A2 (en) 2002-05-29
BR0009163A (pt) 2001-12-26
TWI286938B (en) 2007-09-21
HK1043731B (en) 2009-01-23
EP1880735A3 (en) 2008-03-12
PL203917B1 (pl) 2009-11-30
US20150079125A1 (en) 2015-03-19
HK1043730A1 (zh) 2002-09-27
CN1351503A (zh) 2002-05-29
HU229968B1 (hu) 2015-03-30
NZ513842A (en) 2004-05-28
TR200102739T2 (tr) 2001-12-21
PL355180A1 (en) 2004-04-05
PL355178A1 (en) 2004-04-05
HK1043731A1 (en) 2002-09-27
EP2277535A2 (en) 2011-01-26
EP1776962A1 (en) 2007-04-25
HUS1500040I1 (hu) 2018-05-28
CY2009014I1 (el) 2010-07-28
PL204890B1 (pl) 2010-02-26
TR200102735T2 (tr) 2002-04-22
TR200102736T2 (tr) 2002-04-22
SI1162999T1 (sl) 2007-04-30
HUP0200664A2 (en) 2002-06-29
FR10C0008I2 (fr) 2012-10-26
ATE346608T1 (de) 2006-12-15
AU3813600A (en) 2000-10-09
NZ513840A (en) 2004-02-27
EP2277535A3 (en) 2011-03-09
ES2339737T3 (es) 2010-05-25
WO2000056359A2 (en) 2000-09-28
CZ20013380A3 (cs) 2002-03-13
ES2275499T3 (es) 2007-06-16
IL145043A0 (en) 2002-06-30
CY1107390T1 (el) 2010-07-28
MY125387A (en) 2006-07-31
AR022964A1 (es) 2002-09-04
NZ513841A (en) 2001-09-28
ATE387214T1 (de) 2008-03-15
AU750913B2 (en) 2002-08-01
WO2000056358A3 (en) 2001-01-04
DK1162999T3 (da) 2007-03-26
CA2365296A1 (en) 2000-09-28
US20060093626A1 (en) 2006-05-04
HK1043728A1 (en) 2002-09-27
WO2000056360A3 (en) 2001-01-25
MXPA01009452A (es) 2002-08-06
CN1391481A (zh) 2003-01-15
EP1163000A2 (en) 2001-12-19
WO2000056360A2 (en) 2000-09-28
BRPI0009163B8 (pt) 2021-05-25
HK1043728B (en) 2007-06-22
KR100642044B1 (ko) 2006-11-10
IL145044A (en) 2007-03-08
AU750788B2 (en) 2002-07-25
FR10C0008I1 (fr) 2010-03-26
CZ303653B6 (cs) 2013-01-30
US8926985B2 (en) 2015-01-06
DE60043930D1 (de) 2010-04-15
DE60032120D1 (de) 2007-01-11
DE60032120T2 (de) 2007-09-20
LU91652I9 (instruction) 2019-01-03
US20060002961A1 (en) 2006-01-05
EP1162999A2 (en) 2001-12-19
PT1162999E (pt) 2007-02-28
DK1163000T3 (da) 2008-04-28
KR20020000549A (ko) 2002-01-05
CN1192798C (zh) 2005-03-16
CA2366314A1 (en) 2000-09-28
NO20014323L (no) 2001-11-14
JP2002540075A (ja) 2002-11-26
BR0009166A (pt) 2001-12-26
NO2011014I2 (no) 2011-08-30
CZ301445B6 (cs) 2010-03-03
NO2011014I1 (no) 2011-09-19
HUP0200373A2 (en) 2002-06-29
JP2002540074A (ja) 2002-11-26
US20100119544A1 (en) 2010-05-13
CY2009014I2 (el) 2010-07-28
NO20014322L (no) 2001-11-14
EP1880735A2 (en) 2008-01-23
TWI281403B (en) 2007-05-21
NO20014322D0 (no) 2001-09-05
EP1162999B1 (en) 2006-11-29
CN1351501A (zh) 2002-05-29
NL300415I1 (nl) 2009-12-01
MY125202A (en) 2006-07-31
NO330736B1 (no) 2011-06-27
IL145043A (en) 2007-06-17
BE1025464I2 (instruction) 2019-03-06
CY1107561T1 (el) 2013-03-13
LU91652I2 (fr) 2010-10-13
TWI235064B (en) 2005-07-01
EP1162998A2 (en) 2001-12-19
AU750762B2 (en) 2002-07-25
BR0009154A (pt) 2001-12-26
CZ20013379A3 (cs) 2002-03-13
JP4846906B2 (ja) 2011-12-28
HU228499B1 (en) 2013-03-28
CN1191852C (zh) 2005-03-09
JP2002539273A (ja) 2002-11-19
IL145044A0 (en) 2002-06-30
JP2011057713A (ja) 2011-03-24
IL145045A0 (en) 2002-06-30
PT1163000E (pt) 2008-03-20
US20100291138A1 (en) 2010-11-18
SI1163000T1 (sl) 2008-06-30
CZ20013378A3 (cs) 2002-03-13
WO2000056358A2 (en) 2000-09-28
US20030147922A1 (en) 2003-08-07
NO20014325L (no) 2001-11-14
WO2000056359A3 (en) 2001-02-01
NO330532B1 (no) 2011-05-09
JP5551579B2 (ja) 2014-07-16
AR022965A1 (es) 2002-09-04
NO20014323D0 (no) 2001-09-05
KR100798212B1 (ko) 2008-01-24
BRPI0009163B1 (pt) 2019-04-09
US20050031646A1 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
BE2018C020I2 (instruction)
BE2016C007I2 (instruction)
BE2015C057I2 (instruction)
BE2015C018I2 (instruction)
BE2014C017I2 (instruction)
BE2013C051I2 (instruction)
BE2013C020I2 (instruction)
BE2013C015I2 (instruction)
BE2013C001I2 (instruction)
BE1025464I2 (instruction)
JP2002514480A5 (instruction)
BRPI0017527B8 (instruction)
IN2001KO01233A (instruction)
JP2002521141A5 (instruction)
BRPI0001672A2 (instruction)
JP2002521591A5 (instruction)
JP2002517184A5 (instruction)
JP2002519925A5 (instruction)
JP2002513244A5 (instruction)
JP2002506962A5 (instruction)
BRPI0001542A2 (instruction)
JP2002521163A5 (instruction)
JP2002513606A5 (instruction)
JP2002502016A5 (instruction)
BRPI0012675B8 (instruction)